Drug Overview

Serabelisib is an advanced, investigational medication designed to treat various types of solid tumors. It belongs to a modern group of cancer-fighting drugs that target specific proteins inside cells that help tumors grow and survive. As a precision medicine, it is often tested in combination with other therapies to make them work more effectively.

Because it is an experimental drug, it is currently available only to patients participating in approved clinical research trials. It is not yet available at standard local pharmacies or for general prescription use.

• Generic name: Serabelisib (also known as INK1117 or TAK-117)
• US Brand names: None (Investigational drug)
• Drug Class: PI3K-alpha inhibitor, Small molecule inhibitor
• Route of Administration: Oral (taken by mouth as a tablet or capsule)
• FDA Approval Status: Investigational (Not currently approved by the FDA for standard medical use)

What Is It and How Does It Work? (Mechanism of Action)

Serabelisib is a highly specific Targeted Therapy and is considered a Smart Drug. Unlike traditional chemotherapy, which attacks all fast-growing cells, serabelisib is engineered to find and block a very specific communication pathway that is often broken in cancer cells.

At the molecular level, this drug works by blocking a protein called Phosphoinositide 3-kinase alpha, or PI3K-alpha. In a healthy body, this protein acts like a relay station, sending signals that tell cells when to grow and how to use energy from sugar. However, in many cancers (such as breast, lung, and endometrial cancer), the gene that makes this protein (called PIK3CA) becomes mutated. This mutation causes the relay station to stay in the “on” position permanently.

When the PI3K pathway is always “on,” it sends constant instructions through a chain of proteins called AKT and mTOR. These instructions tell the cancer cells to multiply rapidly and ignore the body’s natural signals to die. Serabelisib binds directly to the alpha version of this protein and shuts it down. By cutting off this specific signal, the drug stops the cancer from growing and can make the tumor more sensitive to other treatments like hormone therapy or chemotherapy.

FDA-Approved Clinical Indications

Because serabelisib is an investigational drug, it does not currently have official FDA-approved indications for the general public. It is being studied in clinical trials for the following areas:

Oncological uses

• Investigational treatment for advanced solid tumors with PIK3CA mutations.
• Investigational treatment for metastatic breast cancer (often used in combination with hormone therapies or other targeted drugs like alpelisib).
• Investigational treatment for advanced endometrial cancer.

Non-oncological

• None at this time.

Dosage and Administration Protocols

In clinical research settings, serabelisib is taken as an oral pill. The exact dose is determined by the specific clinical trial protocol.

Dose Adjustments

Because this drug is processed by the liver and can affect blood sugar levels, dose adjustments are common in trials. If a patient develops severe side effects, doctors may lower the dose or pause the medication. There are no established dose starting rules for renal (kidney) or hepatic (liver) insufficiency outside of trial protocols, but these organs are monitored weekly during treatment.

Clinical Efficacy and Research Results

Clinical research data from 2020 to 2025 have focused on using serabelisib as part of “combination therapy” to overcome drug resistance.

Numerical data from recent trials (such as the study of TAK-117 in combination with other agents) have shown that the drug successfully inhibits the PI3K pathway in human tumors. In trials for advanced breast cancer, combining PI3K inhibitors like serabelisib with hormone therapy has shown an improvement in progression-free survival compared to using hormone therapy alone. For example, similar drugs in this class have been shown to double the time before the disease gets worse in patients with PIK3CA mutations. Researchers are currently using numerical data to find the best “intermittent” dosing schedule to maximize tumor shrinkage while keeping side effects low.

Safety Profile and Side Effects

Serabelisib has a safety profile that is common for drugs that block the PI3K pathway. Because this pathway also helps the body manage sugar, some side effects are metabolic.

Black Box Warning

There is no official FDA Black Box Warning for serabelisib because it is an investigational drug.

Common side effects

These side effects are seen in greater than 10 percent of patients:

• High blood sugar (hyperglycemia)
• Nausea and vomiting
• Diarrhea
• Feeling very tired (fatigue)
• Skin rash
• Decreased appetite

Serious adverse events

• Severe hyperglycemia (dangerously high blood sugar)
• Pneumonitis (inflammation of the lung tissue)
• Severe skin reactions (such as Stevens-Johnson Syndrome)
• Significant increases in liver enzymes (indicating liver stress)

Management strategies

High blood sugar is the most common concern. Patients are often taught to monitor their blood sugar at home. If sugar levels rise, doctors may prescribe diabetes medications like metformin. For skin rashes, steroid creams or antihistamines are used. If lung inflammation is suspected, the drug is stopped immediately and steroids are given.

Research Areas

Serabelisib is a major focus in immunotherapy and regenerative medicine research. PI3K signaling is not just important for cancer cells; it also helps “T-cells” (the immune system’s hunters) decide how to fight. Researchers are studying whether serabelisib can be used to “reprogram” the immune system to make it better at finding hidden cancer cells. There is also early research exploring how PI3K inhibitors can target “cancer stem cells,” which are the stubborn cells that often survive standard chemotherapy and cause the cancer to return years later.

Patient Management and Practical Recommendations

Pre-treatment tests to be performed

• Genetic testing of the tumor to confirm a PIK3CA mutation.
• Fasting blood glucose and Hemoglobin A1c tests to check for diabetes.
• Liver function tests (ALT, AST, and Bilirubin).
• Baseline lung function check or imaging.

Precautions during treatment

Patients must be careful about their diet. Because the drug can cause blood sugar to spike, a low-sugar or low-carb diet is often recommended during the trial. Patients must also be monitored for any new cough or shortness of breath.

Do’s and Don’ts list

• Do monitor your blood sugar at home as instructed by your trial team.
• Do report any new or worsening skin rashes immediately.
• Do take your medication at the same time every day to keep drug levels steady.
• Don’t ignore signs of high blood sugar, such as extreme thirst or frequent urination.
• Don’t take any other new medications or herbal supplements without asking your oncologist, as they can interfere with the drug’s effectiveness.
• Don’t stop taking the medication suddenly without talking to your medical team.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Serabelisib is an investigational medication and is not approved by the FDA for the treatment of any disease. Always consult with a qualified oncologist or healthcare professional before participating in a clinical trial or starting a new medical treatment.